{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:45:34Z","timestamp":1787165134142,"version":"build-2736575974"},"reference-count":23,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Haemophagocytic lymphohistiocytosis (\n                    <jats:styled-content style=\"fixed-case\">HLH<\/jats:styled-content>\n                    ) is a severe, even fatal, inflammatory condition. Epstein\u2013Barr virus (\n                    <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content>\n                    ) infection\u2010associated\n                    <jats:styled-content style=\"fixed-case\">HLH<\/jats:styled-content>\n                    (\n                    <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content>\n                    \u2010\n                    <jats:styled-content style=\"fixed-case\">HLH<\/jats:styled-content>\n                    ) is one of the most common types of secondary\n                    <jats:styled-content style=\"fixed-case\">HLH<\/jats:styled-content>\n                    . Etoposide is a key drug in\n                    <jats:styled-content style=\"fixed-case\">HLH<\/jats:styled-content>\n                    \u201094\/04 regimen. We sought to identify the importance of etoposide in the initial treatment of\n                    <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content>\n                    \u2010\n                    <jats:styled-content style=\"fixed-case\">HLH<\/jats:styled-content>\n                    . Ninety\u2010three patients with\n                    <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content>\n                    \u2010\n                    <jats:styled-content style=\"fixed-case\">HLH<\/jats:styled-content>\n                    of all ages admitted to our centre in 2017 were divided into two groups according to whether the initial treatment contained etoposide or not. The survival of the group whose initial therapy included etoposide (Group 1, 52 patients; 6\u2010month survival rate 0\u00b7769) was significantly better than that of the group whose initial therapy did not include etoposide (Group 2, 41 patients; 6\u2010month survival rate 0\u00b7269) (\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0&lt;\u00a00\u00b7001). In patients aged &lt;18\u00a0years old, the survival of Group 1 patients was not significantly better than that of Group 2 patients (\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00\u00b7447), in contrast to patients aged \u226518\u00a0years, where the survival of Group1 patients was significantly better than that of Group 2 patients (\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0&lt;\u00a00\u00b7001). We concluded that including etoposide in the initial treatment of\n                    <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content>\n                    \u2010\n                    <jats:styled-content style=\"fixed-case\">HLH<\/jats:styled-content>\n                    patients can improve their prognosis, especially adult patients. This may be because that adult patients are recognized as \u201chigher risk\u201d patients.\n                  <\/jats:p>","DOI":"10.1111\/bjh.15988","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T05:34:16Z","timestamp":1558503256000},"page":"717-723","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Requirement for etoposide in the initial treatment of Epstein\u2010Barr virus\u2013associated haemophagocytic lymphohistiocytosis"],"prefix":"10.1111","volume":"186","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0898-5281","authenticated-orcid":false,"given":"Yue","family":"Song","sequence":"first","affiliation":[{"name":"Department of Haematology Beijing Friendship Hospital Capital Medical University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yini","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Haematology Beijing Friendship Hospital Capital Medical University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Haematology Beijing Friendship Hospital Capital Medical University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,5,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21795"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13102"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12386"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.05.031"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0172"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3181f84a52"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.10.2665"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.10314"},{"key":"e_1_2_7_11_1","first-page":"183","article-title":"Longitudinal follow\u2010up of patients with Epstein\u2010Barr virus\u2010associated hemophagocytic lymphohistiocytosis","volume":"89","author":"Imashuku S.","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.605"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302282"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24980"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.638"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24188"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2010.04.012"},{"key":"e_1_2_7_18_1","first-page":"672","article-title":"Assessment of immunochemotherapy and stem cell transplantation on EBV\u2010associated hemophagocytic lymphohistiocytosis in children: a systematic review and meta analysis","volume":"16","author":"Qin Q.","year":"2012","journal-title":"European Review for Medical and Pharmacological Sciences"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24039"},{"key":"e_1_2_7_20_1","first-page":"5738","article-title":"The ambiguous boundary between EBV\u2010related hemophagocytic lymphohistiocytosis and systemic EBV\u2010driven T cell lymphoproliferative disorder","volume":"7","author":"Smith M.C.","year":"2014","journal-title":"International Journal of Clinical and Experimental Pathology"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2011.01.027"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-644914"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0317-7"},{"key":"e_1_2_7_24_1","first-page":"507","article-title":"Treatment outcomes and prognostic analysis of 61 Epstein\u2010Barr virus\u2010associated hemophagocytic lymphohistiocytosis","volume":"36","author":"Zeng X.","year":"2015","journal-title":"Zhonghua xue ye xue za zhi = Zhonghua Xueyexue Zazhi"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15988","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.15988","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15988","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T01:36:08Z","timestamp":1694309768000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,22]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1111\/bjh.15988"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15988","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,22]]},"assertion":[{"value":"2019-01-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}